Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) .fwdarw.4)-β-D-Glcp-(1.fwdarw.4)-[Gro-(2.fwdarw.P.fwdarw.3)]-β-D-Galp-(1.fwdarw.4)-β-L-Rhap-(1.fwdarw.. Also provided are conjugates comprising a .fwdarw.4)-β-D-Glcp-(1.fwdarw.4)-[Gro-(2.fwdarw.P.fwdarw.3)]-β-D-Galp-(1.fwdarw.4)-β-L-Rhap-(1.fwdarw., immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) .fwdarw.4)-β-D-Glcp-(1.fwdarw.4)-[Gro-(2.fwdarw.P.fwdarw.3)]-β-D-Galp-(1.fwdarw.4)-β-L-Rhap-(1.fwdarw.. Also provided are conjugates comprising a .fwdarw.4)-β-D-Glcp-(1.fwdarw.4)-[Gro-(2.fwdarw.P.fwdarw.3)]-β-D-Galp-(1.fwdarw.4)-β-L-Rhap-(1.fwdarw., immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

The present invention relates to immunogenic compositions comprising immunogenic polypeptides from Haemophilus influenzae and Moraxella catarrhalis and their use in the treatment or prevention of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a subject, e.g. human.

The present invention is directed to a gram-negative bacterial host cell for vaccine use comprising a heterologous functional Actinobacillus pleuropneumoniae (APR) rfb gene cluster producing an APR O-anti-gen bound to the lipid A-core of the bacterial host cell and located on the bacterial host outer surface, and wherein the endogenous rib gene cluster of the bacterial host cell is not functional. The invention further pertains to compositions comprising said host cells, in particular vaccines, and corresponding uses in the prophylaxis and/or therapy of Actinobacillus pleuropneumoniae (APR) infections.

The present invention is directed to a gram-negative bacterial host cell for vaccine use comprising a heterologous functional Actinobacillus pleuropneumoniae (APR) rfb gene cluster producing an APR O-anti-gen bound to the lipid A-core of the bacterial host cell and located on the bacterial host outer surface, and wherein the endogenous rib gene cluster of the bacterial host cell is not functional. The invention further pertains to compositions comprising said host cells, in particular vaccines, and corresponding uses in the prophylaxis and/or therapy of Actinobacillus pleuropneumoniae (APR) infections.